TW201111378A - Substituted (heteroarylmethyl) thiohydantoins - Google Patents

Substituted (heteroarylmethyl) thiohydantoins Download PDF

Info

Publication number
TW201111378A
TW201111378A TW099127804A TW99127804A TW201111378A TW 201111378 A TW201111378 A TW 201111378A TW 099127804 A TW099127804 A TW 099127804A TW 99127804 A TW99127804 A TW 99127804A TW 201111378 A TW201111378 A TW 201111378A
Authority
TW
Taiwan
Prior art keywords
group
methyl
trifluoromethyl
keto
dimethyl
Prior art date
Application number
TW099127804A
Other languages
English (en)
Chinese (zh)
Inventor
Ulrich Luecking
Arwed Cleve
Bernard Haendler
Hortensia Faus
Silke Koehr
Horst Irlbacher
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of TW201111378A publication Critical patent/TW201111378A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW099127804A 2009-09-11 2010-08-19 Substituted (heteroarylmethyl) thiohydantoins TW201111378A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09075421 2009-09-11
EP10075069 2010-02-17

Publications (1)

Publication Number Publication Date
TW201111378A true TW201111378A (en) 2011-04-01

Family

ID=42782041

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099127804A TW201111378A (en) 2009-09-11 2010-08-19 Substituted (heteroarylmethyl) thiohydantoins

Country Status (28)

Country Link
US (1) US20120251551A1 (enExample)
EP (1) EP2475653A1 (enExample)
JP (1) JP2013504523A (enExample)
KR (1) KR20120065396A (enExample)
CN (1) CN102639523A (enExample)
AR (1) AR078166A1 (enExample)
AU (1) AU2010294588A1 (enExample)
BR (1) BR112012005526A2 (enExample)
CA (1) CA2773591A1 (enExample)
CL (1) CL2012000623A1 (enExample)
CO (1) CO6511228A2 (enExample)
CR (1) CR20120113A (enExample)
CU (1) CU20120042A7 (enExample)
DO (1) DOP2012000063A (enExample)
EA (1) EA201200473A1 (enExample)
EC (1) ECSP12011716A (enExample)
IL (1) IL218390A0 (enExample)
IN (1) IN2012DN02081A (enExample)
MA (1) MA33566B1 (enExample)
MX (1) MX2012002977A (enExample)
NZ (1) NZ598643A (enExample)
PE (1) PE20121180A1 (enExample)
PH (1) PH12012500497A1 (enExample)
SG (1) SG178919A1 (enExample)
TN (1) TN2012000108A1 (enExample)
TW (1) TW201111378A (enExample)
UY (1) UY32882A (enExample)
WO (1) WO2011029537A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011216404B2 (en) 2010-02-17 2016-04-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2011150457A2 (en) * 2010-06-01 2011-12-08 The University Of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
AU2012358803C1 (en) 2011-12-22 2019-12-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
JP6284547B2 (ja) 2012-12-21 2018-02-28 アリオス バイオファーマ インク. 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN104341351B (zh) * 2013-07-30 2018-02-06 北京海美源医药科技有限公司 一种二芳基硫代乙内酰脲衍生物及其应用
LT3080100T (lt) * 2013-12-11 2023-02-27 Celgene Quanticel Research, Inc. Lizinui specifinės demetilazės-1 inhibitoriai
US20160318897A1 (en) 2013-12-18 2016-11-03 Basf Se Azole compounds carrying an imine-derived substituent
US9682960B2 (en) * 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
JP6479854B2 (ja) 2014-05-07 2019-03-06 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングEvotec International GmbH 医薬組成物のためのスルホキシイミン置換キナゾリン
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
JP6888000B2 (ja) 2015-10-08 2021-06-16 バイエル ファーマ アクチエンゲゼルシャフト 新規な修飾された大環状化合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
TW201900604A (zh) 2017-05-18 2019-01-01 印度商Pi工業公司 新穎的脒化合物
US11701347B2 (en) 2018-02-13 2023-07-18 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma
WO2020209933A1 (en) * 2019-04-11 2020-10-15 University Of Miami Improved inhibitors of the notch transcriptional activation complex and methods for use of the same
EP4093512A1 (en) * 2020-01-21 2022-11-30 The United States of America, as represented by the Secretary, Department of Health and Human Services Aryl hydantoin heterocycles and methods of use
CN117120436A (zh) * 2021-03-30 2023-11-24 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法
WO2025103470A1 (zh) * 2023-11-17 2025-05-22 中国药科大学 作为雄激素受体(ar)拮抗剂的化合物及其应用
CN120309588B (zh) * 2025-06-10 2025-08-12 上海健康医学院 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
KR100660309B1 (ko) 1998-09-22 2006-12-22 아스텔라스세이야쿠 가부시키가이샤 시아노페닐 유도체
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CA2482382A1 (en) 2002-04-12 2003-10-23 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
CA2529292A1 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Oxazolidinone antibiotics and derivatives thereof
TW200526637A (en) 2003-09-30 2005-08-16 Janssen Pharmaceutica Nv Benzoimidazole compounds
HRP20100675T1 (hr) 2003-12-23 2011-01-31 Astex Therapeutics Limited Derivati pirazola kao modulatori protein kinaze
ATE503746T1 (de) 2004-08-03 2011-04-15 Chugai Pharmaceutical Co Ltd Neue imidazolidinderivate
CN101676270A (zh) * 2004-09-09 2010-03-24 中外制药株式会社 新型四氢咪唑衍生物及其用途
WO2006058649A1 (en) 2004-12-03 2006-06-08 F. Hoffmann-La Roche Ag 3-substituted pyridine derivatives as h3 antagonists
RS52274B2 (sr) 2005-05-13 2018-05-31 Univ California Jedinjenje diarilhidantoina
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
CA2648139A1 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders
US8680291B2 (en) 2007-10-26 2014-03-25 The Regents Of The University Of California Diarylhydantoin compounds
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Also Published As

Publication number Publication date
BR112012005526A2 (pt) 2016-04-26
DOP2012000063A (es) 2012-05-15
US20120251551A1 (en) 2012-10-04
AR078166A1 (es) 2011-10-19
JP2013504523A (ja) 2013-02-07
IN2012DN02081A (enExample) 2015-08-21
MA33566B1 (fr) 2012-09-01
MX2012002977A (es) 2012-04-30
CL2012000623A1 (es) 2012-09-14
PE20121180A1 (es) 2012-08-24
TN2012000108A1 (en) 2013-09-19
IL218390A0 (en) 2012-04-30
ECSP12011716A (es) 2012-04-30
CU20120042A7 (es) 2012-06-21
NZ598643A (en) 2013-10-25
CO6511228A2 (es) 2012-08-31
CA2773591A1 (en) 2011-03-17
AU2010294588A1 (en) 2012-04-05
CR20120113A (es) 2012-05-02
CN102639523A (zh) 2012-08-15
EA201200473A1 (ru) 2012-10-30
EP2475653A1 (en) 2012-07-18
WO2011029537A1 (en) 2011-03-17
UY32882A (es) 2011-04-29
PH12012500497A1 (en) 2012-10-22
KR20120065396A (ko) 2012-06-20
SG178919A1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
TW201111378A (en) Substituted (heteroarylmethyl) thiohydantoins
JP6534675B2 (ja) mIDH1阻害剤としてのベンズイミダゾール−2−アミン
CA2772790C (en) Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
US9555022B2 (en) Substituted triazolopyridines
TW201211049A (en) Substituted imidazopyridazines
JP5951750B2 (ja) 置換イミダゾピリジン類およびその中間体
JP6001049B2 (ja) Mps−1キナーゼ阻害剤としての置換ベンズイミダゾール類
RS53670B1 (sr) Triazolopirimidini
EP2507233A1 (en) Substituted triazolopyridines
CN102282142A (zh) 取代的芳族化合物和它们的用途
TW201245194A (en) Triazolopyridines
JP6166289B2 (ja) 置換イミダゾピリダジン
AU2014347644B2 (en) Carboxymethyl piperidine derivative
CN103282351A (zh) 取代的苯氧基吡啶
HK1170732A (en) Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs
HK1164851A (en) Heteroaromatic compounds for use as hif inhibitors
TW201217336A (en) Chemical compounds